Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22423696 | 0.85 | ALDH1A1 (0.58) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL301815 | 0.83 | TSHR (0.68) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL22289781 | 0.82 | ALDH1A1 (0.75) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL21113658 | 0.82 | TSHR (0.69) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL20267422 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPK1 | |
| SCHEMBL21113695 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL4626793 | 0.81 | TSHR (0.64) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL1554746 | 0.80 | ALDH1A1 (0.85) | ALDH1A1LMNATSHRTDP1L3MBTL1 | |
| SCHEMBL302145 | 0.80 | TSHR (0.66) | ALDH1A1TSHRTDP1TP53CYP3A4 | |
| SCHEMBL16051215 | 0.78 | ALDH1A1 (0.68) | ALDH1A1LMNATSHRTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019198109-A1 | NOVEL PHARMACEUTICAL COMPOSITION OF ESSENTIAL OIL | ZIM LABORATORIES LIMITED (IN) | 2019-10-17 | — | — | WO | claimed |
| US-12023365-B2 | Sustained release formulations of Crocus sativus | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-07-02 | — | — | US | disclosed |
| WO-2024073056-A1 | CUCURBITURIL COMPOSITIONS, PRODUCTS, AND METHODS OF USE | Kureha America, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20200390843-A1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-12-17 | — | — | US | disclosed |
| EP-3697389-A1 | SUSTAINED RELEASE FORMULATIONS OFCROCUS SATIVUS | Council of Scientific and Industrial Research (IN) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019198109-A1 | NOVEL PHARMACEUTICAL COMPOSITION OF ESSENTIAL OIL | ZIM LABORATORIES LIMITED (IN) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019077621-A1 | SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-04-25 | — | — | WO | disclosed |
| EP-1257269-B1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | KOPRAN RES LAB LTD (IN) | 2004-11-03 | — | — | EP | disclosed |
| US-6617338-B2 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2003-09-09 | — | — | US | disclosed |
| US-20030023091-A9 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | US | disclosed |
| EP-1257269-A1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | Kopran Research Laboratories Limited (IN) | 2002-11-20 | — | — | EP | disclosed |
| US-20020038032-A1 | Orally administrable acid stable antiulcer benzimidazole derivatives | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2002-03-28 | — | — | US | disclosed |
| WO-2001062248-A1 | ORALLY ADMINISTRABLE ACID STABLE ANTI-ULCER BENZIMIDAZOLE DERIVATIVES | KOPRAN RESEARCH LABORATORIES LIMITED (IN) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023091-A9 | Orally administrable acid stable antiulcer benzimidazole derivatives | SI, PGA5, PAICS | ALDH1A1 1143/4885LMNA 1613/4885TSHR 4746/4885 |
| US-20020038032-A1 | Orally administrable acid stable antiulcer benzimidazole derivatives | SI, PGA5, PAICS | ALDH1A1 1143/4885LMNA 1613/4885TSHR 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.